Kinvard Bio is creating a new class of antibiotics to treat drug-resistant infections and diseases.

Scientists zoom in on microbial messages at the molecular level to understand how the microbiome shapes health.

Sponsored research agreement between Harvard and Roche resulted in the Kahne Lab’s discovery of the mechanism of action for Roche’s compound, paving the way for the development of new antibiotics.

Harvard University and Ono Pharmaceutical Co. (ONO) have launched a strategic alliance today to advance research across a broad range of therapeutic areas.